Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Merck KGaA and Palantir Collaborate to Speed Drug Development

By Merck KGaA | January 13, 2017

Merck KGaA, Darmstadt, Germany, and Palantir launch new healthcare acceleration partnership.

Merck KGaA, Darmstadt, Germany, a science and technology company, announced a partnership with Palantir Technologies, developer of sophisticated data integration and analysis software, at Palantir’s headquarters in Palo Alto, CA. The partnership will leverage Palantir’s advanced data analytics capabilities to help Merck KGaA better and more rapidly develop and deliver medicines to patients, commercialize new products, and improve patient outcomes.

Initially Merck KGaA will apply Palantir’s technology to cancer treatment and patient services. Ultimately Merck KGaA plans to deploy Palantir’s technology across all three of the company’s business sectors Healthcare, Life Science and Performance Materials. Financial details were not disclosed.

“As a science and technology company, we are tackling the greatest challenges in healthcare, life science and performance materials. Now we are teaming up with Palantir since developing breakthrough technologies requires superior data analytics capabilities, and Palantir optimally complements our skills in that respect,” said Stefan Oschmann, chairman of the executive board and CEO of Merck KGaA, during the announcement of the partnership on Thursday.

“At the heart of Palantir’s mission is the desire to bring new tools to solve the world’s most difficult problems,” said Alexander Karp, founder and CEO of Palantir. “When something like cancer is killing 8.2 million people each year, we want to do everything we can to apply our technological expertise to the fight, alongside partners who have been there since the beginning. We are pleased to have found a partner that shares our values and vision.”

The partnership will launch with three initiatives within the Healthcare business sector of Merck KGaA.

  • Medical Research & Drug Development: The partnership will increase precision of the drug development process by developing a collaborative data and analytics platform so that researchers of Merck KGaA can analyze real-world and bioinformatics data to understand the patients who may benefit most. 
  • Global Patient Intimacy: The partnership will improve the experience of patients using products of Merck KGaA by utilizing large-scale data sources to increase adherence and understand real-world drug efficacy. 
  • Global Supply Chain: The data and analytics platform of Merck KGaA and Palantir will improve supply chain forecasting and agility in order to provide medicines to patients around the world with maximum speed and reliability. 

Biomedical research generates unprecedented volumes of rapidly evolving data every day. But accessing, learning from, and expanding on those assets has become a huge bottleneck in scientists’ ability to bring new innovations from the bench to the bedside. Through their combined effort, Merck KGaA and Palantir will aim to harness the power locked inside that data for the benefit of patients.

Palantir Technologies software products are currently deployed by financial institutions, NGO’s, government agencies and other organizations to solve mission critical data driven problems in intelligence, defense, law enforcement, data protection, health care and global finance among other areas. Palantir’s platform is built to manage sensitive information while giving institutions the tools to effectively protect privacy.

(Source: PR Newswire)


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50